Soleno Therapeutics (SLNO) Non-cash Items (2017 - 2026)

Soleno Therapeutics (SLNO) has 10 years of Non-cash Items data on file, last reported at $103.6 million in Q1 2026.

• Quarterly Non-cash Items fell 20.3% year-over-year to $103.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.6 million (down 20.3% YoY) and the FY2025 annual result came in at $47.4 million, down 40.42% from the prior year.
• Non-cash Items improved to $103.6 million in Q1 2026 per SLNO's latest filing, from $47.4 million in the prior quarter.
• Across five years, Non-cash Items topped out at $130.0 million in Q1 2025 and bottomed at $3.2 million in Q4 2022.
• The 5-year median for Non-cash Items is $70.1 million (2024), against an average of $55.4 million.
• The widest annual swing landed in 2024, when Non-cash Items soared 2358.16%; it then tumbled 40.42% in 2025.
• Tracing SLNO's Non-cash Items over 5 years: stood at $3.2 million in 2022, then surged by 2113.56% to $70.8 million in 2023, then increased by 12.34% to $79.6 million in 2024, then sank by 40.42% to $47.4 million in 2025, then soared by 118.5% to $103.6 million in 2026.
• Per Business Quant, the three latest SLNO Non-cash Items figures stand at $103.6 million (Q1 2026), $47.4 million (Q4 2025), and $113.6 million (Q3 2025).

Peer Comparison